Inhibition of Murine Nephritogenic Effector T Cells by a Clone-specific Suppressor Factor

Catherine M. Meyers* and Carolyn J. Kelly†‡
* Renal-Electrolyte Division and † Immunology Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Abstract

We have used a murine model of organ-specific autoimmunity to characterize therapeutic modalities capable of down-regulating the cellular limb of the autoimmune response. Murine interstitial nephritis is an autoimmune disease mediated by tubular antigen-specific CD8+ nephritogenic effector T cells which are delayed-type hypersensitivity (DTH) reactive and cytotoxic to renal epithelial cells. Previous studies have demonstrated that disease can be suppressed with experimentally induced populations of T cells (Ts1 and Ts2 cells) obtained after injection of tubular antigen-coupled splenocytes into syngeneic mice. As the target of Ts2 is the CD8+ effector T cell, we have evaluated its effects on nephritogenic effector T cell clones isolated from diseased animals. Our studies demonstrate that soluble proteins expressed by Ts2 cells (TsF2) specifically abrogate the DTH, cytotoxic, and nephritogenic potential of M52 cells, although T cell receptor and IL-2 receptor expression are unchanged in these unresponsive M52 clones. TsF2-induced inhibition is dependent on new mRNA and protein synthesis. In a cytotoxic clone, M52.26, exposure to TsF2 induces expression of TGF-β1 which is, in turn, required for inhibition of cytotoxicity and nephritogenicity. Our studies are consistent with TGF-β1 behaving, at least in some T cells, as a nonspecific final effector of clone-specific suppression. (J. Clin. Invest. 1994. 94:2093–2104.) Key words: autoimmunity ♦ αTBM disease ♦ nephritogenic T cells ♦ immune suppression ♦ T cell receptors

Introduction

The development of immunosuppressive modalities targeting injurious cellular immune responses has enormous intrinsic appeal as well as broad potential clinical applications. Several approaches to the development of such modalities have been taken in both autoimmune disease models and experimental transplant rejection. For example, immunosuppressive modalities which target only some T cell phenotypes (1–3), cell-surface determinants preferentially expressed on activated T cells (4, 5), or restricted T cell receptor (TCR)† variable regions (6–9) are efficacious therapies for several experimental autoimmune diseases. An ideal immunosuppressive modality, however, would be antigen or clone specific, targeting only those T cells involved in the autoimmune, or alloreactive, response. This type of immunosuppression could theoretically be achieved through preferential expansion of specific suppressor T cells in the host.

Studies performed in several autoimmune disease models induced by immunization have demonstrated that alternate means of antigen presentation can preferentially induce the expansion of T cells which inhibit disease expression. These techniques include immunization with large amounts of antigen in incomplete Freund’s adjuvant (10, 11), or intravenous injection of antigen chemically coupled to splenocytes (12–14). The latter method is one initially used to induce hapten-specific suppressor T cells (15, 16). In a murine model of autoimmune kidney disease, anti-tubular basement membrane (αTBM) disease, intravenous injection of tubular antigen coupled to splenocytes prevents the characteristic inflammatory lesion in the renal interstitium and also improves the histologic lesion in animals with established disease (17, 18). The adoptive transfer of specific T cell populations from the recipients of tubular antigen-coupled splenocytes inhibits induced T cell responses to tubular antigen and the histologic expression of disease, strongly supporting the hypothesis that Ts cells are an important component of this immunosuppression (18).

The intravenous injection of tubular antigen-coupled splenocytes into SJL mice (H-2b) induces two phenotypically and functionally distinct populations of Ts cells (18). The CD4+ suppressor T cells (Ts1) inhibit an early stage in the differentiation of the nephritogenic CD8+ effector T cells which mediate αTBM disease, and also induce a population of CD8+ suppressor T cells (18–20). These CD8+ Ts cells (Ts2), or soluble proteins secreted by Ts2 cells (TsF2), directly inhibit the function of bulk populations of tubular antigen-specific CD8+ effector cells through a noncytotoxic mechanism (18, 19). While the molecular definition of suppressor factors is still controver-

---

1. Abbreviations used in this paper: αTBM, anti-tubular basement membrane; SRITA, soluble renal tubular antigen; PPD, purified protein derivative; 3M-1, the nephritogenic moiety in SRTA; CTL, cytotoxic T lymphocyte; MCT, murine proximal tubular epithelial cell line; MTT, 3(4,5-dimethylthiazoyl-2-yl)2,5-diphenyltetrazolium bromide; EAE, experimental allergic encephalomyelitis; IL-2R, receptor for IL-2; TCR, T cell receptor for antigen; VB variable region of the TCR β chain; CB, constant region of the TCR β chain; RT/PCR, reverse transcription PCR.
sial, increasing evidence supports their being closely related to conventional TCR chains (21–24).

We have been interested in developing highly targeted immunotherapy for autoimmune disease and in delineating the cellular and molecular events which define a "suppressed" T cell. We have recently characterized a panel of nephrigenic effector T cell clones specific for 3M-1, a glycoprotein target antigen of aTBDM disease (25, 26). These cultured CD8+ T cells, called M52, maintain the functional capacity of nephrigenic effector T cells induced in vivo (26). Class I MHC-restricted M52 cells mediate 3M-1-specific delayed-type hypersensitivity (DTH) and cytotoxic responses, and adoptively transfer interstitial nephritis to naive syngeneic recipients. Analysis of M52 clones has revealed two distinct functional subsets within the M52 cell line. One subset is cytotoxic and not DTH reactive to the target antigen 3M-1. The other subset is DTH reactive but effects less efficient cytotoxicity to 3M-1-expressing tubular epithelial cells (26). Since previous studies suggest that these clones should be the direct target of TsF2 (18, 19), we were in a unique position to characterize the state of clonal inactivation resulting from coculture with a suppressor factor. Our studies show that co-culture with TsF2 results in functional inactivation of nephrigenic M52 cells. TsF2 inhibits both cytotoxic and DTH-reactive clones and abrogates the nephrigenic potential of M52 cells in adoptive transfer studies. This inhibitory activity is specific for M52 cells. Metabolic inhibitor studies indicate that TsF2-induced suppression of M52 is dependent on new mRNA and protein synthesis. In the cytotoxic clone, one of these induced mRNA species is TGF-β1, which is required for TsF2-induced suppression of cytotoxicity and nephritogenicity.

Methods

Mice. SJL mice (H-2b) were purchased from the Jackson Laboratory (Bar Harbor, ME).

Antigens and antibodies. Rabbit renal tubular basement membranes were isolated by a differential sieving technique, sonicated, lyophilized, and stored at −20°C (27). Soluble renal tubular antigen (SRTA) was made from these lyophilized membranes by collagenase digestion (28). The nephrigenic moiety in this digestion, the 3M-1 glycoprotein, is purified from SRTA using immunoaffinity chromatography with a mAb (25). P1, a synthetic peptide derived from the cDNA sequence of 3M-1 (LLRRHHGRDRTMSAEEV) was manually synthesized by the simultaneous multiple peptide method of Houghten (29, 30). Purified protein derivative (PPD) was obtained from Connaught Laboratories, Ltd. (Willowdale, Ontario, Canada). Neutralizing antibody to TGF-β1 and normal chicken IgY were purchased from R&D Systems, Inc. (Minneapolis, MN).

Metabolic inhibitors. Cordycepin (3′-deoxyadenosine), an inhibitor of polyadenylation, and emetine, an inhibitor of protein synthesis, were purchased from Sigma Chemical Co. (St. Louis, MO).

T cell lines (M52 and M61) and clones. CD8+ T cell lines and clones were isolated from immunized mice as previously described (26) and propagated by weekly passage with 20 μg/ml antigen (SRTA, P1, or PPD), 20% MLA-144 supernatants as a source or IL-2 and other growth factors (31), and 5 × 10^4 irradiated (2,500 rads) syngenic spleen cells. T cell culture medium consisted of RPMI 1640 (Whittaker M. A. Bioproducts, Inc., Walkersville, MD) supplemented with glutamine, antibiotics (penicillin, streptomycin, gentamicin), 10% decomponent FCS, 5% NCTC-109 (Whittaker M. A. Bioproducts, Inc.), and 2 × 10^-5 M 2-ME. Typically, wells became confluent at 4–5 d and were carried every 7 d. All T cells were cultured at 37°C in a 5% CO2 incubator.

Murine kidney cell line. MCT (SJL proximal tubular epithelial) cells were grown at 37°C and 5% CO2 in DME (JRH Biosciences, Lenexa, KS) with 10% FCS (32). They were used as confluent target cells for cytotoxicity assays.

Preparation of soluble TsF2. CD8+ Ts2 (suppressor-effector) cells were induced by a 5-d co-culture of CD4+ M40 suppressor-inducer cell supernatants (TsF1) (20% vol/vol), with naive syngeneic splenocytes in T cell medium, SRTA (20 μg/ml), and MLA-144 supernatants (19, 20). Induced splenocytes were then depleted with aCD4 Ab (from GK 1.5 hybridoma [33]) and a mixture of guinea pig and rabbit C. Freezethaw lysates were made of the remaining CD8+ T cells. For some studies, control lysates of induced CD4+ and other CD8+ cells were prepared similarly. Lysates of CD4+ T cells induced by TsF1 were prepared after incubation of induced splenocytes with aCD8 Ab (from hybridoma 3.1688 [34]) and C. The other control lysate was made from CD8+ T cells induced by supernatants of CD4+ Th cells (M30F) (35). After a 5-d coculture of M30F with syngeneic splenocytes, T cell medium, SRTA (20 μg/ml), and MLA-144 supernatants, CD8+ T cells were isolated by depletion with aCD4 Ab and C. These lysates were quantitated in cell equivalents, i.e., a lysate derived from 5 × 10^6 cells was described as 5 × 10^6 cell equivalents. In some studies, these lysates were added to day 3 cultured T cells (0.5 × 10^6 cell equivalents added per well of a 24-well plate), and 24 h later cultures were washed and replated in fresh T cell medium, IL-2, and antigen. Cells were harvested for functional studies or RNA extraction on day 7 of culture.

Local adoptive transfer of DTH. The adoptive transfer of DTH has been described in detail (26, 36). In brief, cultured T cells were washed and resuspended at 2.0 × 10^7 cells/ml in 1 mg/ml of SRTA, PPD, P1, or PBS, and 25 μl of each cell preparation were injected into the hind footpad of recipient mice (3–4 mice/group). Footpad swelling as an index of DTH was measured 24 h later using a spring-loaded engineer’s micrometer (model 7308; Mitutoyo/MTI Corp., Paramus, NJ). The magnitude of swelling was expressed as the mean increment between the antigen-challenged footpad and that injected with PBS in inches × 10^−2 SEM. In some experiments, T cell subpopulations were selectively depleted by incubation with aCD8 or aCD4 mAb and C. All footpad measurements were performed by an individual blinded to the experimental protocol.

Adaptive transfer of disease. These adaptive transfers have been previously described (26, 36). In brief, naive SJL mice were anesthetized, and 25 × 10^6 cultured lymphocytes (either M52 or TsF2-pulsed M52 cells) in 75 μl of PBS were injected under the kidney capsule, with a 30-gauge needle. This volume uniformly lifted the capsule off most of the parenchyma without bleeding. 7 d later the kidneys were harvested and longitudinally sectioned with preservation of the subcapsular cell layer. After fixation in 10% buffered formalin, the kidneys were paraffin embedded for staining with hematoxylin and eosin. The kidneys were then examined histologically for the presence of interstitial injury.

Assessment of renal disease. The stained kidney sections were coded for blind reading by two different grading scales. The severity was qualitatively assessed using a scale modified from previous studies (26, 36): 0, no involvement of the subcapsular cell layer; 0.5, trace pathologic changes of cellular involvement in a focal pattern in the outermost cortical tubular area; 1, superficial, focal peritubular infiltration and tubular atrophy under the transferred cell layer; 2, focal, deeply extending, heavy cellular infiltrates with peritubular damage and tubular atrophy. The sections were also graded by approximating the tubular layer cell depth of the infiltrating front of mononuclear cells. Each layer equaled a tubular diameter and was given one point. The data from both methods were expressed as a mean for each group ± SEM.

Cytotoxicity assays. This method determines target cell viability (37, 38), and has been described in detail previously (26). In brief, the MCT target cells were prepared from confluent cultures by light trypsination from tissue culture flasks and washed once in serum-containing medium. Cells were then resuspended at 1.0 × 10^6/ml in medium containing 0.5 μg/ml mitomycin C (Sigma Chemical Co.), vigorously vortexed, then 20-μl aliquots were dispensed into 96-well flat-bottomed
microtiter plates. 180 µl of mitomycin C–containing medium (0.5 µg/ml) was then added to each well. Adherent target cells were allowed to attach by overnight incubation at 37°C, 5% CO₂. Effector T cells were harvested from day 5 cultures containing irradiated syngeneic feeders, IL-2, and antigen, and separated by Lympholyte (Cedarlane Labs, Ltd., Hornby, Ontario, Canada) extraction at room temperature. The interface cell layer containing effector T cells was washed with fresh medium and resuspended at 10 × 10⁶ cells/ml. Appropriate aliquots were then added to the adherent target cells at effector/target (E/T) ratios of 5:1–100:1 in triplicate. Plates were incubated for 16–20 h at 37°C and 5% CO₂. Four wells containing target cells received no effector cells as a control for MCT cell viability and four wells containing only medium were used to control for nonspecific dye reduction. After effector cell incubation, T cells were washed from the microtiter wells with warmed (37°C) medium, and the wells were replated with 180 µl of fresh medium. 20 µl of MTI dye (Sigma Chemical Co.) solution (5 mg/ml in PBS) was added to each well and the plate was incubated for 4 h at 37°C, 5% CO₂. After this incubation, medium and unrelated dye were aspirated from the wells and 180 µl of 0.04 N HCl in isopropyl alcohol were added to solubilize the formazan dye. In addition, 20 µl of 3% SDS solution was added to solubilize alcohol-induced protein precipitates. The OD at 570 nm of each well was then determined using a spectrophotometer (Beckman Instrs., Inc., Fullerton, CA). The mean and standard deviation were determined for triplicate samples. The percent cytotoxicity was calculated by the following equation: percent cytotoxicity = (1 – OD treated/OD control) × 100.

**Cytofluorography.** Cytofluorography was performed on M52 clones harvested from day 9 cultures. Cells were washed in PBS, and aliquots of 1 × 10⁶ cells were resuspended in 50 µl PBS with 0.1% BSA (staining buffer). Monoclonal antibodies to the αβ/αTCR (39) and the γδ TCR (40) (Pharmingen, La Jolla, CA), and to the IL-2 receptor (IL-2R) (41) were incubated with samples on ice for 20 min, and washed three times with staining buffer. Samples receiving a fluoresceinated secondary antibody (Pharmingen) were then incubated with the appropriate antibody for 20 min on ice, and washed three times. Stained cells were fixed with 4% paraformaldehyde in PBS. Fluorescence was recorded on a FACScan cytofluorograph (Becton Dickinson, Mountain View, CA). In each run, 10,000 live gated cells were analyzed.

**RNA-extraction.** Total cellular RNA was isolated from cultured T cells, after isolation with Lympholyte (Cedarlane Labs, Ltd.), by the single-step method of acid guanidium thiocyanate-phenol-chloroform extraction (42). The extracted RNA was washed with 80% ethanol, vacuum-dried and resuspended in diethyl pyrocarbonate-treated water. After assessing the purity of the final products by optical density ratios at 260:280 nm, which were typically > 1.7, the RNA samples were then used for Northern blot analyses or reverse transcribed into cDNA for the polymerase chain reaction.

**Northern blot hybridization.** Total RNA isolated from 6 × 10⁶ T cells was fractionated on a 1.5% agarose-formaldehyde gel and then transferred to a Zetabind membrane (Cuno Inc., Meriden, CT). Prehybridization and hybridization were conducted at 55°C in 0.5 M Na₂PO₄ buffer, 7% SDS, 1% BSA, and 1 mM EDTA with 50 µg/ml polyadenylic acid (Boehringer Mannheim Biochemicals, Indianapolis, IN) and 50–100 µg/ml sheared salmon sperm DNA. Blots were hybridized to 32P-labeled (random-primed) murine probes (specific activity of 2.0 × 10⁶ dpm/µg) for 16 h at 55°C. Probes for TCR β (43), IL-2 (44), IFN-γ (45), TGF-β (46), perforin (47), and β-actin (48) were used in these studies. After hybridization the blots were washed three times with 0.1× SSC/0.1% SDS at 65°C for 30 min. Autoradiography was performed with intensifying screens at −70°C.

**PCR amplification of T cell transcripts.** Reverse transcription of 10 µg of T cell RNA was performed with 0.25 mM dNTPs (Boehringer Mannheim Biochemicals), 40 U of recombinant RNASin (Promega, Madison, WI), 0.01 M DTT, 0.3 µg oligo(dT)₁₅, 1× HRT buffer, and 500 U of M-MLV reverse transcriptase (all from Bethesda Research Laboratories, Gaithersburg, MD). The reaction mixture was incubated at 37°C for 60 min, heat inactivated at 95°C for 5–10 min, and then quick-chilled on ice. PCR was performed with 1× PCR buffer II (Perkin–Elmer Corp., Norwalk, CT), final concentration 50 mM KCl, 10 mM Tris HCl, and 1.0 mM MgCl₂ solution (Perkin–Elmer Corp.), 0.20 mM dNTP (Boehringer Mannheim Biochemicals), 0.40 pmol each 3′ and 5′ primer, and 1.25 U of Thermus aquaticus DNA polymerase (Taq polymerase) (Perkin–Elmer Corp.) in a total volume of 100 µl. The mixture was overlaid with mineral oil and then amplified with a Perkin–Elmer Corp. thermal cycler. The amplification profile involved 35 cycles of denaturation at 92°C for 1 min, primer annealing at 50°C for 1 min, and extension at 72°C for 2 min. 10 µl of each PCR reaction mixture was electrophoresed in a 2% agarose gel. Gels were stained with ethidium bromide and photographed.

**Oligonucleotides used for amplification.** Oligonucleotides were synthesized on a DNA synthesizer (Applied Biosystems, Foster City, CA). The sense (5′ primer) and antisense (3′ primer) sequences used for these PCR reactions and the source of the published murine cytokine sequences are as listed in Table I.

**Statistical analysis.** Differences between experimental groups were determined by Student’s t test, where appropriate. Cytotoxicity curves were evaluated using two-way analysis of variance (49).

**Results**

TsF₂ suppresses effector cell DTH reactivity to SRTA. The M52 cell line mediates multiple functions including DTH reactivity, cytotoxicity, and adoptive transfer of interstitial nephritis. We began our studies by first analyzing the effects of TsF₂ on the DTH reactivity of the M52 cell line and clones to the target antigen 3M-1. As shown in Table II, M52 cells treated with TsF₂ for 24 h do not display DTH reactivity to tubular antigen by day 7 of culture. Since TsF₂ is a cell lysate preparation, we prepared several other control lysates in order to examine the possibility of a nonspecific inhibitory effect of the TsF₂ prepara-
Table II. TsF2 Suppresses M52 DTH Reactivity to Tubular Antigen

<table>
<thead>
<tr>
<th>Donor cells</th>
<th>Lysate added to culture*</th>
<th>Injected antigen</th>
<th>DTH response*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M52</td>
<td>—</td>
<td>SRTA</td>
<td>19.7±0.9</td>
</tr>
<tr>
<td>M52</td>
<td>TsF2</td>
<td>SRTA</td>
<td>2.7±1.2</td>
</tr>
<tr>
<td>M52 (6 mo)*</td>
<td>TsF2</td>
<td>SRTA</td>
<td>4.0±1.5</td>
</tr>
<tr>
<td>M52</td>
<td>CD4* lysate</td>
<td>SRTA</td>
<td>18.7±0.7</td>
</tr>
<tr>
<td>M52</td>
<td>CD8* lysate</td>
<td>SRTA</td>
<td>19.0±0.6</td>
</tr>
<tr>
<td>M61</td>
<td>TsF2</td>
<td>PPD</td>
<td>19.3±2.8</td>
</tr>
</tbody>
</table>

* TsF2 and the control lysates (CD4* lysate and CD8* lysate) were prepared as described in Methods. The appropriate cell lysate (0.5×10^6 cell equiv/well) was then added to day 3 cultured T cells. 24 h later the cells were harvested, washed in T cell media, and replated in fresh media, IL-2, and antigen (SRTA or PPD, 20 μg/ml). Cells were tested on day 7 of culture. † Values are expressed as the mean of three mice in inches×10^-3±SEM. They represent the incremental difference in footpad swelling, measured 24 h after challenge, between the footpad that received 0.5×10^6 cells plus antigen (SRTA or PPD, 1 mg/ml) and that which received 0.5×10^6 cells and PBS. ‡ After exposure to only a single dose of TsF2, these cells were then carried in culture for many months with weekly passage. § P < 0.001 compared with M52 cells alone.

Table III. TsF2 Suppresses DTH Reactivity of M52 Clones to Tubular Antigen

<table>
<thead>
<tr>
<th>Donor cells</th>
<th>Injected antigen</th>
<th>Control</th>
<th>TsF2-pulsed</th>
<th>DTH Response*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M52.23</td>
<td>P1</td>
<td>20.3±0.9</td>
<td>1.0±0.6</td>
<td></td>
</tr>
<tr>
<td>M52.28</td>
<td>P1</td>
<td>18.7±1.2</td>
<td>2.3±0.3</td>
<td></td>
</tr>
<tr>
<td>M52.34</td>
<td>P1</td>
<td>19.0±1.2</td>
<td>2.3±0.3</td>
<td></td>
</tr>
<tr>
<td>—</td>
<td>—</td>
<td>1.7±0.3</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>

* See † of Table II, values are expressed as the mean of three mice in inches×10^-3±SEM. † See * of Table II. M52 clones were pulsed with TsF2 on day 3 of culture and injected day 7 to assess DTH reactivity. ‡ P < 0.001 compared to control, untreated M52 clone.

Antigen-specific cytotoxicity toward 3M-1—expressing tubular epithelial cells (MCT) in a dose-dependent manner. Both the M52 cell line and M52.26 (a CTL clone) are cytotoxic to MCT between E/T ratios of 5:1 and 50:1, where cytotoxicity approaches 80%. In order to test the effects of TsF2 on this interaction, M52.26 cells were pulsed with TsF2 for 24 h, and then tested for cytotoxicity to MCT cells. As shown in Fig. 1, M52.26 cells pretreated with TsF2 demonstrate a marked decrease in cytotoxicity toward tubular epithelial cells in culture.

M52 cells pulsed with TsF2 do not infiltrate the kidney following adoptive transfer. We next examined the ability of TsF2-pulsed M52 cells to elicit an inflammatory interstitial lesion following adoptive transfer. We have previously shown that M52 cells infiltrate the kidney of syngeneic recipients and produce severe interstitial injury after adoptive transfer (26). In the present studies we confirmed the nephritogenicity of M52 cells (Fig. 2, A and B, Table IV). The recipients of these cells were sacrificed 7 d after cell transfer and the kidneys evaluated by light microscopy for both severity of injury and maximum depth of the infiltrating cell front (26, 36). Areas of involvement in these kidneys consisted of focal mononuclear infiltrates as well as areas of tubular atrophy and dilation. In contrast to these lesions, adoptive transfer of TsF2-treated cells did not

![Figure 1. TsF2 inhibits M52.26-mediated cytotoxicity.](http://www.jci.org)
Figure 2. Subcapsular cell transfers. Cultured M52 cells, untreated (A and B) or pulsed with TsF2 (C and D), were injected under the kidney capsule of naive syngeneic mice. After 7 d, the kidneys were harvested and sectioned for histologic grading. The interstitial lesion typically seen after transfer of M52 cells is seen in both A and B. Focal cortical areas of mononuclear cell infiltration are apparent, as well as areas of tubular atrophy and dilatation. M52 cells pretreated with TsF2 do not infiltrate the renal parenchyma, as seen in C and D. The interstitial architecture remains normal, and focal subcapsular collections of mononuclear cells are evident (A–D, ×200).

Table IV. TsF2 Abrogates the Nephritogenicity of M52

<table>
<thead>
<tr>
<th>Cells injected*</th>
<th>Treatment</th>
<th>Histology after subcapsular transfer</th>
<th>Severity</th>
<th>Maximum depth</th>
</tr>
</thead>
<tbody>
<tr>
<td>M52</td>
<td>—</td>
<td></td>
<td>1.8±0.1</td>
<td>19.3±1.1</td>
</tr>
<tr>
<td>M52</td>
<td>TsF2</td>
<td></td>
<td>0.1±0.1P</td>
<td>2.3±1.3P</td>
</tr>
<tr>
<td>M61</td>
<td>—</td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* Cultured T cells were harvested from day 7 cultures. In some groups, cells were pretreated with TsF2 on day 3 of culture. 25 x 10⁶ cells in 75 μl of PBS were injected under the kidney capsule of naive SJL mice. n = 4 for each group. ¹7 d after transfer, the kidneys were harvested and sectioned for histologic grading as detailed in Methods. ²P < 0.05 compared with M52 cells injected.

result in any significant interstitial pathology (Fig. 2, C and D). A formal histologic grading of the two groups is depicted in Table IV, and demonstrates that TsF2 markedly inhibits the ability of M52 cells to cause autoimmune injury. One of four recipients of TsF2-pulsed cells had a small area of mild and superficial inflammation. The other three animals had no detectable renal damage.

TsF2-treated effector cells maintain TCR expression. As previously stated, TsF2-pulsed M52 cells and clones restimulated with fresh irradiated splenocytes, IL-2, and antigen, continue to proliferate well but remain unreactive in functional assays. Recent studies in models of induced anergy have suggested that in some cases anergy may be accompanied by diminished cell surface expression of the TCR (51, 52). To further evaluate loss of antigen recognition by TsF2-pulsed M52 clones, we examined them for cell-surface TCR expression. Our previous studies have demonstrated that M52 clones express αβ TCR (26). The Northern hybridization study shown in Fig. 3 was
TsF₂-pulsed M52 clones maintain TCR expression. 10 μg of total RNA derived from M52 clones, either untreated or pulsed with TsF₂, was electrophoresed, blotted, and hybridized to a Cβ probe. The intact TCR-β message (1.3 kb) is present in all clones tested.

conduct with a 32P-labeled Cβ probe, and compares β chain mRNA expression in M52 clones before and after exposure to TsF₂. The 1.3-kb band apparent in all lanes corresponds to the intact TCR-β message, and is unaffected by TsF₂ suppression. In addition, cytofluorographic analyses of TsF₂-pulsed M52 clones demonstrate persistent cell surface expression of αβ TCR (Fig. 4), unchanged in intensity from that previously reported for active M52 clones (26). FACS analyses of these clones also demonstrated unchanged IL-2R expression (Fig. 5), consistent with their continued ability to proliferate in response to IL-2.

TsF₂ function requires new mRNA and protein synthesis. To better understand the cellular processes which result in TsF₂-induced suppression of M52 cells, we next evaluated whether suppression was an active process, requiring new mRNA and protein synthesis. M52 cells were pulsed with both TsF₂ and varying concentrations of either 3′-deoxyadenosine (an inhibitor of polyadenylation) or emetine (an inhibitor of protein synthesis). 24 h later the cells were washed and replated, and then tested for DTH reactivity at day 7. As shown in Table V, TsF₂-induced suppression was blocked by either inhibitor in a dose-dependent manner. 1 μg/ml of 3′-deoxyadenosine does not inhibit TsF₂ suppression whereas 50 μg/ml completely eliminates suppression. Similarly, emetine at 10 ng/ml, but not 1 ng/ml, completely eliminates suppression. Inhibitors added to M52 cultures in the absence of TsF₂ did not result in augmented DTH responses, arguing against this being a nonspecific effect of the inhibitors independent of TsF₂. These studies support the notion that TsF₂-mediated suppression is an active cellular process which requires new mRNA and protein synthesis.

TsF₂-mediated changes in effector cell cytokine gene transcription. Recent studies have demonstrated that some murine T cell clones (CD4⁺) express distinct cytokine profiles which correlate with function (53, 54). We have made similar observations in characterizing the expression of cytokines in M52 clones. Our qualitative cytokine analyses were conducted using the reverse transcription/polymerase chain reaction (RT/PCR) technique in which 10 μg of RNA from M52 clones was reverse transcribed, and PCR conducted with primers amplifying defined segments of specific cytokine transcripts. As shown in Fig. 6, M52 clones of different functional phenotypes exhibit distinct cytokine profiles when tested for expression of a panel of relevant cytokines, including IL-2, IL-4, IL-6, IFN-γ, TNF-α, TGF-β, and a cytotoxic mediator, perforin. The pattern seen with M52.34 is representative of most DTH-reactive clones. We could amplify an appropriate size band for all tested cytokines from M52.34 cDNA (Fig. 6 A), but even with such a highly sensitive technique we could not demonstrate the presence of a perforin transcript. The cytotoxic clone, M52.26, con-

Figure 3. TsF₂-pulsed M52 clones maintain TCR expression. 10 μg of total RNA derived from M52 clones, either untreated or pulsed with TsF₂, was electrophoresed, blotted, and hybridized to a Cβ probe. The intact TCR-β message (1.3 kb) is present in all clones tested.

Figure 4. Cell surface expression of TCR on TsF₂-treated M52 clones. Day 9 cultured M52 clones, which had been pulsed with TsF₂ on Day 3, (A) M52.23, (B) M52.26, (C) M52.28, (D) M52.34, were incubated with FITC-hamster anti–mouse TCR Abs. αβ TCR Ab (——), γδ TCR Ab (−−−).
consistently displayed a different pattern of cytokine expression, as shown in Fig. 6B. M52.26 expresses a perforin transcript and all tested cytokines, except for IL-2 and TGF-β. Since these patterns are highly reproducible, in our hands, for a given T cell clone, we used this as a screening technique to determine whether the TsF2-induced change in M52 function was also associated with a change in cytokine gene expression. The RNA used for these analyses was harvested from TsF2-pulsed clones at a time when the cells were functionally inactive. Fig. 6 also reveals the cytokine pattern of both a cytotoxic (M52.26) and a DTH-reactive (M52.34) clone after pretreatment with TsF2, and exhibits changes from baseline studies of functional M52 clones. In the cytotoxic clone, IL-2 message remains undetectable, but TGF-β expression is induced, and perforin and IFN-γ expression is lost. In the DTH-reactive clone, IL-2 expression is no longer apparent but the expression of other cytokines is maintained, although the intensity of amplified PCR products for several cytokines was consistently diminished. To further investigate quantitative changes in cytokine expression, we performed Northern hybridization studies. The results of these studies, shown in Fig. 7, confirm the major cytokine changes observed in M52 clones following TsF2 treatment, and also reveal
Table V. TsF2 Function Requires New mRNA and Protein Synthesis

<table>
<thead>
<tr>
<th>Pretreatment of M52 cells*</th>
<th>Inhibitors added to M52 cells†</th>
<th>DTH response to SRTA‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>—</td>
<td>—</td>
<td>18.3±1.9</td>
</tr>
<tr>
<td>TsF2</td>
<td>—</td>
<td>5.0±0.6†</td>
</tr>
<tr>
<td>TsF2</td>
<td>3-DA (1 μg/ml)</td>
<td>4.0±1.0†</td>
</tr>
<tr>
<td>TsF2</td>
<td>3-DA (10 μg/ml)</td>
<td>9.7±3.4</td>
</tr>
<tr>
<td>TsF2</td>
<td>3-DA (50 μg/ml)</td>
<td>21.7±3.0</td>
</tr>
<tr>
<td>—</td>
<td>3-DA (50 μg/ml)</td>
<td>19.7±2.2</td>
</tr>
<tr>
<td>TsF2</td>
<td>Emetine (1 ng/ml)</td>
<td>4.7±0.3†</td>
</tr>
<tr>
<td>TsF2</td>
<td>Emetine (10 ng/ml)</td>
<td>15.0±2.1</td>
</tr>
<tr>
<td>TsF2</td>
<td>Emetine (100 ng/ml)</td>
<td>16.3±0.9</td>
</tr>
<tr>
<td>—</td>
<td>Emetine (100 ng/ml)</td>
<td>17.7±0.7</td>
</tr>
</tbody>
</table>

* TsF2 was added to day 3 M52 cultures (0.5 × 10⁶ cell equiv/well). 24 h later the cells were harvested, washed, and replated in fresh medium, IL-2, and SRTA (1 mg/ml). Cells were again harvested on Day 7 and injected into naive recipient SJL mice. † Varying concentrations of either 3-deoxyadenosine (3-DA), an inhibitor of polyadenylation, or emetine, an inhibitor of protein synthesis, were added to day 3 M52 cultures with TsF2, and then washed as described above. ‡ See Table II, values are expressed as the mean of three mice in inches × 10⁻³ ± SEM. § P < 0.001 compared with M52 cells injected alone.

A reduction of IFN-γ expression in TsF2-treated DTH-reactive clones. Fig. 7B shows the induction of TGF-β and the loss of perforin and IFN-γ in the cytokitic clone, M52.26. The lack of IL-2 expression in the DTH-reactive clones is also apparent. TsF2 inactivation of M52.26-mediated cytotoxicity and nephritogenicity is reversed by neutralizing antisera to TGF-β1. Our screening for cytokine transcripts by RT-PCR revealed only one (TGF-β1) which was induced in a TsF2-treated clone (M52.26). Given the studies supporting a requirement for new mRNA and protein synthesis to see suppression, we next examined whether neutralizing antisera to TGF-β1 would interfere with TsF2-mediated suppression of M52.26. Fig. 8 demonstrates that neutralizing antisera to TGF-β1 (10 μg/ml) completely

Figure 6. Analysis of cytokine and perforin (or murine P1) production of untreated and TsF2-pulsed M52 clones by RT/PCR of total RNA. Amplified fragments of anticipated size were detected by ethidium bromide staining of 1.8% agarose gels. (A) Representative pattern of DTH-reactive clones, M52.34. (B) Cytokine profile of M52.26, a CTL clone.

Figure 7. Northern hybridization studies of TsF2-induced changes in M52 clonal cytokine expression. 10 μg of total RNA derived from untreated and TsF2-pulsed M52 clones was electrophoresed, blotted onto a nylon membrane, and hybridized with cytokine probes. (A) The DTH-reactive clones, M52.23, M52.28, and M52.34 were evaluated for their expression of IL-2 and IFN-γ, and (B) M52.26, a CTL, was examined for its expression of IFN-γ, TGF-β1, and perforin. The lower panels reveal the hybridization of the blots to a β-actin probe and demonstrate the relative amount of RNA loaded in each lane.

Figure 8. Neutralizing αTGF-β Ab inhibits TsF2-mediated suppression of CTL activity. The cytotoxic potential of clone M52.26 toward tubular epithelial cells was evaluated, using the MTT assay, with untreated M52.26 (○), and M52.26 pretreated with TsF2 (●), TsF2 + αTGF-β Ab (10 μg/ml) (●), or TsF2 + IgG (10 μg/ml) (●). Each data point represents the mean of triplicate samples. The asterisk denotes statistical significance of the curve (P < 0.05) from M52.26 based on two-way analysis of variance.
abrogates the TsF2-mediated suppression of M52.26 cytotoxicity to tubular epithelial cells. Normal chicken IgY had no effect. This concentration of neutralizing αTGF-β1 blocks 95–100% of the effect of 0.25 ng/ml of TGF-β1 on IL-4-dependent [³H]-thymidine incorporation by HT-2 cells (R & D specifications, neutralizing dose50 is 2–3 μg/ml). Neutralizing αTGF-β1 has no augmenting effect on M52.26-mediated cytotoxicity to MCT cells in the absence of TsF2 (data not shown), consistent with our previous findings (Figs. 6 and 7) that TGF-β1 is not expressed by M52.26 cells in the absence of TsF2.

The importance of TGF-β1 in TsF2-mediated suppression of M52.26 is further underscored by the analysis of adoptive transfer studies displayed in Table VI. M52.26 cells treated with TsF2 and the αTGF-β1 antibody from day 3 of culture were nephritogenic compared with those treated with TsF2 with or without the control IgY. While the lesions seen in the group receiving both TsF2 and αTGF-β1 antibody had the same histologic features (mononuclear cells and tubular dilatation) as those seen in untreated M52.26 cells, the numerical severity and depth indices were significantly less. This difference may reflect a difference in the duration of action of TsF2 versus αTGF-β1 antibody, since the TsF2 functional effect persists (Table II) while the neutralizing capability of the antibody is likely lost when the cells are harvested, washed, and resuspended in PBS for adoptive transfer.

**Discussion**

The concept that T cells can be functionally inhibited in an antigen- or clone-specific manner by the product of another T cell is certainly not a novel one. A number of investigators have described this phenomenon and have distinguished the effects of antigen-specific suppressor factors (TsFs) from nonspecific inhibitory cytokines (such as TGF-β) as well as from cytotoxicity or the absence of help (55–57). Research in the area of antigen-specific suppression became highly controversial in the 1980’s, when Ts hybridomas were shown not to express conventional TCR (58) and the molecular definition of TsFs remained unclear. In the past several years though, investigators working in several distinct antigenic systems have unequivocally demonstrated the presence of conventional αβ TCR on Ts hybrids and clones (23, 56, 59). Recent studies strongly support a long-standing hypothesis that these suppressor factors are comprised, at least in part, of conventional TCR polypeptides (21, 22, 24, 59). These findings have rekindled an interest in exploring the potential of antigen-specific immunosuppression for the therapy of autoimmune disease and transplant rejection.

Evidence that regulatory T cells can have a profound impact on both histologic abnormalities and functional organ impairment exists in several models of autoimmunity, including αTBM disease (11, 17, 18, 20, 60), interstitial nephritis in kkdd mice (61), insulin-dependent diabetes in NOD mice (62, 63), thyroiditis (10, 64), and experimental allergic encephalomyelitis (EAE) (12, 14, 65). How Ts cells function to impair autoimmune T and/or B cell clones is less clear. Previous work in murine αTBM disease demonstrated that bulk populations of the CD8⁺ effector T cells could be functionally inhibited in a noncytotoxic manner by CD8⁺ splenocytes (or cell lysates) from recipients of Ag-coupled splenocytes (18). In this study we used four previously characterized nephritogenic T cell clones (26) to more closely examine the mechanism of their inactivation.

We first confirmed that the inhibitory effect of the cell lysate, TsF2, is specific for the M52 clones and also not a nonspecific effect of a lysate preparation. TsF2 functionally inhibits both cytotoxic clones and DTH-reactive clones and, perhaps most importantly, the ability of these T cells to elicit an inflammatory response in the interstitium of the kidney after adoptive transfer. Previous studies in this model demonstrated that the CD8⁺ Ts cells and TsF2 are anti-idiotypic and that this might provide a structural basis for their interaction with idiotype-expressing CD8⁺ effector T cells (18). The recent observations from the rat model of EAE that TCR Vβ8 region peptides can induce or augment anti-Vβ8 T cells and antibodies provides a structural basis for such an idiotypic–antiidiotype interaction as well as another example of how this interaction can be immunosuppressive in the setting of organ-specific autoimmunity (7, 8). In EAE the encephalitogenic T cells preferentially utilize the Vβ8.2 gene (6, 66) and therefore induced anti-Vβ8 immune responses can effectively target the majority of encephalitogenic clones. The target of TsF2 may be intact M52 TCR or processed TCR peptides. We are presently investigating the V regions used by these clones.

Although we were initially impressed that exposure to TsF2 induced an indefinite state of unresponsiveness, this finding is consistent with the complete inhibition of nephritogenic T cell expression and disease activity documented in previous studies (18–20). The fact that the cell line and clones continued to grow well immediately after exposure to TsF2 and when repassed, led us to examine whether we could identify some alteration in cell-surface receptors or cytokine expression which might explain their inability to function. While we cannot rule out an alteration in a cell-surface molecule, TCR expression and IL-2R expression are unchanged from their baseline level of expression in functional clones. There are, however, characteristic and reproducible alterations in cytokine expression in M52 clones after exposure to TsF2.

Many investigators have described modifications of RT/PCR techniques which allow for quite precise quantitation of transcript copy number (67). Our use of RT-PCR was as a

<table>
<thead>
<tr>
<th>Cells injected*</th>
<th>Pretreatment</th>
<th>Severity</th>
<th>Maximum depth</th>
</tr>
</thead>
<tbody>
<tr>
<td>M52.26</td>
<td>—</td>
<td>1.9±0.1</td>
<td>32.2±2.8</td>
</tr>
<tr>
<td>M52.26</td>
<td>TsF2</td>
<td>0⁺</td>
<td>0⁺</td>
</tr>
<tr>
<td>M52.26</td>
<td>TsF2 + αTGF-β1 Ab (10 μg/ml)</td>
<td>1.0±0.1</td>
<td>16.3±1.9</td>
</tr>
<tr>
<td>M52.26</td>
<td>TsF2 + Control Ab (10 μg/ml)</td>
<td>0⁺</td>
<td>0⁺</td>
</tr>
</tbody>
</table>

* Cultured T cells clones were harvested from day 7 cultures. In some groups, cells were pretreated with TsF2, αTGF-β1 Ab, or an irrelevant Ab (chicken IgY) on day 3 of culture. 25 × 10⁶ cells in 75 μl of PBS were injected under the kidney capsule of naive SIL mice. n = 3–5 for each group. ⁷ 7 d after transfer, the kidneys were harvested and sectioned for histologic grading as detailed in Methods. ⁶ p < 0.001 compared with M52.26 cells injected.
screening technique to demonstrate major alterations in specified cytokine transcripts. As a screen, we have found the general pattern and relative intensity of amplified cytokine PCR products is highly reproducible both with the same starting template and from one experiment to the next. It is a useful technique to analyze T cell clones which have not been transformed, since it minimizes the number of cells required.

We were intrigued to find that the loss of function induced by TsF2 is dependent upon new RNA and protein synthesis. These inhibitor studies suggest that at some point, suppression is an active process. An analogy may be made to in vitro models of T cell unresponsiveness induced by chemical pretreatment of the antigen-presenting cell or exposure of T cells to antigen complexed to purified MHC in planar membranes (68–70). The induction phase of unresponsiveness in these systems is also an active process requiring new protein synthesis, as it can be blocked by cycloheximide (70). It is interesting that a critical event in these anergic CD4+ clones appears to be the marked reduction in IL-2 production after T cell activation although IL-2R expression is maintained, as are normal levels of TCR expression (68, 69). We have made similar observations in our studies of TsF2 inhibition of M52 clones. The distinction, however, is that in these other models of T cell unresponsiveness, CD4+ cells recover function after restimulation with antigen and IL-2. The functional inhibition we observe with M52 is not readily reversible.

The cytokine alterations we have observed in TsF2-pulsed clones persist as well. The observation that these alterations are closely correlated temporally with loss of function suggests that they are relevant changes. It is reasonable to hypothesize that a clone which can no longer express IL-2 and proliferate in situ may not be able to elicit an inflammatory interstitial lesion. Lower levels of IFN-γ expression may additionally impair a local DTH reaction in the interstitium of the kidney. In the purely cytotoxic clone, M52.26, TsF2 exposure results in loss of perforin gene expression and a marked decrease in its ability to kill tubular epithelial cells. This observation is intriguing to us for several reasons. The mechanisms of cytotoxicity by CTL clones continues to be an active area of research and there is still controversy regarding the physiologic significance of perforin-expressing CTL (71–73). M52.26, our most efficient CTL (26), is the only M52 clone analyzed thus far which expresses perforin. Our findings that a maneuver that shuts off perforin expression is associated with significant inhibition of cytotoxicity, is strong suggestive evidence that perforin is an important mediator of cytotoxicity for M52.26. Since the other M52 clones are also cytolytic to MCT cells (26) (albeit less efficiently), our studies support the existence of perforin-independent modes of CTL action as well as autoimmune effector T cells.

The consistent finding that TGF-β1 expression is induced in M52.26 following exposure to TsF2, was particularly intriguing, in view of multiple studies supporting a role for TGF-β in suppression of T cell functions (74–78). The absence of TGF-β expression by M52.26 when active additionally suggested that TGF-β may be one of the induced mRNA species required for suppression (Table V). The studies performed with neutralizing antisera to TGF-β1 unequivocally demonstrate that TGF-β1 is required for TsF2-mediated suppression of M52.26. Ongoing studies in our laboratory suggest that exogenously added TGF-β1 is also sufficient as a single signal to inhibit M52.26 mediated cytotoxicity and nephritogenicity (78a). Studies in EAE have also demonstrated suppression-related changes in effector T cell cytokine expression (79). In this model, CD4+ Ts inhibit IFN-γ, but not IL-2 expression in effector T cells of EAE, and recent investigations have implicated TGF-β in these TsF2-mediated effects (80, 81). It is quite plausible that once TsF2 has induced TGF-β expression in a T cell such as M52.26, the clone in effect inactivates itself. Such a regulatory mechanism in vivo could locally downregulate T cell–mediated responses and disease activity. This explanation, however, does not apply to clones such as M52.34, which expresses TGF-β1 following activation and are not inactivated by exogenous TGF-β1. The mechanism by which TsF2 inactivates such clones is under active investigation.

Acknowledgments

The authors are grateful to Hank Fletcher for assistance with the cryotofluorography.

This work was supported in part by National Institutes of Health grants DK-42155, DK-08343, and DK-45346. C. M. Meyers is the recipient of a Clinician Scientist Award (91-4090) from the American Heart Association. C. J. Kelly was a Lucille P. Markey Scholar (86-019) and this work was also supported by the Lucille P. Markey Charitable Trust.

References


